News

Important Averitas press releases.

Press Releases

Press
Releases

Aachen, Germany & Morristown, N.J. – 21 July 2020

Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

  • Neuropathic pain associated with diabetic peripheral neuropathy is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20201.
  • QUTENZA® is the first and only topical, non-systemic, non-opioid pain treatment of its kind to deliver prescription strength capsaicin directly into the skin.

Aachen, Germany & Morristown, N.J. – 21 July 2020 — Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.2 QUTENZA® is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin.

Read more